![]()  | Up a level | 
Journal Article
 
 
    
    Cibula, David, Mallmann, Peter, Knapp, Pawel, Melichar, Bohuslav, Klat, Jaroslav 
ORCID: 0000-0001-9762-1345, Minar, Lubos, Novotny, Zdenek, Wimberger, Pauline, Hein, Alexander, Spisek, Radek, Bartunkova, Jirina, Pecen, Ladislav, Bin Hassan, Hariz Iskandar and Rob, Lukas
  
(2018).
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
 
      
    J. Clin. Oncol., 36 (15).
    
    
    
     ALEXANDRIA:
     AMER SOC CLINICAL ONCOLOGY.
     ISSN 1527-7755
  
  
 
 
    
    Cibula, David, Rob, Lukas 
ORCID: 0000-0003-3770-651X, Mallmann, Peter, Knapp, Pawel, Klat, Jaroslav, Chovanec, Josef, Minar, Lubos, Melichar, Bohuslav, Hein, Alexander, Kieszko, Dariusz, Pluta, Marek, Spacek, Jiri, Bartos, Pavel, Wimberger, Pauline, Madry, Radoslaw, Markowska, Janina, Streb, Joanna, Valha, Petr, Bin Hassan, Hariz Iskandar, Pecen, Ladislav, Galluzzi, Lorenzo, Fucikova, Jitka, Hrnciarova, Tereza, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
  
(2021).
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
 
      
    Gynecol. Oncol., 162 (3).
     S. 652 - 661.
    
    
     SAN DIEGO:
     ACADEMIC PRESS INC ELSEVIER SCIENCE.
     ISSN 1095-6859
  
  
 
 
    
    Rob, Lukas 
ORCID: 0000-0003-3770-651X, Cibula, David, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
  
(2021).
Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.
 
      
    J. Clin. Oncol., 39 (15).
    
    
    
     PHILADELPHIA:
     LIPPINCOTT WILLIAMS & WILKINS.
     ISSN 1527-7755
  
  
 
 
    
    Rob, Lukas 
ORCID: 0000-0003-3770-651X, Cibula, David 
ORCID: 0000-0001-6387-9356, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
  
(2022).
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
 
      
    J. Immunother. Cancer, 10 (1).
    
    
    
     LONDON:
     BMJ PUBLISHING GROUP.
     ISSN 2051-1426
  
  
 
 
    
    Rob, Lukas, Mallmann, Peter, Knapp, Pawel, Melichar, Bohuslav, Klat, Jaroslav 
ORCID: 0000-0001-9762-1345, Minar, Lubos, Novotny, Zdenek, Bartunkova, Jirina, Spisek, Radek, Pecen, Ladislav, Bin Hassan, Hariz Iskandar and Cibula, David
  
(2018).
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.
 
      
    J. Clin. Oncol., 36 (15).
    
    
    
     ALEXANDRIA:
     AMER SOC CLINICAL ONCOLOGY.
     ISSN 1527-7755
  
  
		